Skip to main content
Log in

The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Non-motor symptoms are gaining relevance in Parkinson’s disease (PD) management but little is known about their progression and contribution to deterioration of quality of life. We followed prospectively 707 PD patients (62 % males) for 2 years. We assessed non-motor symptoms referred to 12 different domains, each including 1–10 specific symptoms, as well as motor state (UPDRS), general cognition, and life quality. Hoehn & Yahr (H&Y) stage was used to categorize patient status (I–II mild; III moderate; IV–V severe). We found that individual non-motor symptoms had variable evolution over the 2-year follow-up with sleep, gastrointestinal, attention/memory and skin disturbances (hyperhidrosis and seborrhea) becoming more prevalent and psychiatric, cardiovascular, and respiratory disorders becoming less prevalent. Development of symptoms in the cardiovascular, apathy, urinary, psychiatric, and fatigue domains was associated with significant life-quality worsening (p < 0.0045, alpha with Bonferroni correction). During the observation period, 123 patients (17 %) worsened clinically while 584 were rated as stable. There was a fivefold greater increase in UPDRS motor score in worse compared with stable patients over 24 months (p < 0.0001 vs. baseline both in stable and worse group). The total number of reported non-motor symptoms increased over 24 months in patients with motor worsening compared to stable ones (p < 0.001). Thirty-nine patients died (3.4 % of patients evaluable at baseline) with mean age at death of 74 years. Deceased patients were older, had significantly higher H&Y stage and motor score, and reported a greater number of non-motor symptoms at baseline. In conclusion, overall non-motor symptom progression does not follow motor deterioration, is symptom-specific, and only development of specific domains negatively impacts quality of life. These results have consequences for drug studies targeting non-motor features.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P et al (2006) International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson’s disease: the NMSQuest study. Mov Disord 21:916–923

    Article  PubMed  Google Scholar 

  2. Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, Odin P, Macphee G et al (2007) Prevalence of nonmotor symptoms in Parkinson’s disease in an international setting; study using nonmotor symptoms questionnaire in 545 patients. Mov Disord 22:1623–1629

    Article  PubMed  Google Scholar 

  3. Barone P, Antonini A, Colosimo C, Marconi R, Morgante L, Avarello TP, Bottacchi E et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord 24:1641–1649

    Article  PubMed  Google Scholar 

  4. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P et al (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911

    Article  PubMed  Google Scholar 

  5. Simuni T, Sethi K (2008) Non-motor manifestations of Parkinson’s disease. Ann Neurol 64(Suppl 2):S65–S80

    PubMed  Google Scholar 

  6. Beiske AG, Loge JH, Rønningen A, Svensson E (2009) Pain in Parkinson’s disease: prevalence and characteristics. Pain 141:173–177

    Article  PubMed  CAS  Google Scholar 

  7. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T et al (2009) Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468–1474

    Article  PubMed  Google Scholar 

  8. Barone P, Poewe W, Albrecht S et al (2010) Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:573–580

    Article  PubMed  CAS  Google Scholar 

  9. Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-dopa responsive problems dominate at 15 years. Mov Disord 20:190–199

    Article  PubMed  Google Scholar 

  10. Buter TC, van den Hout A, Matthews FE, Larsen JP, Brayne C, Aarsland D (2008) Dementia and survival in Parkinson disease: a 12-year population study. Neurology 70:1017–1022

    Article  PubMed  CAS  Google Scholar 

  11. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8(5):464–474

    Article  PubMed  CAS  Google Scholar 

  12. Antonini A, Colosimo C, Marconi R, Morgante L, Barone P (2008) The PRIAMO Study: background, methods and recruitment. Neurol Sci 29:61–65

    Article  PubMed  Google Scholar 

  13. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442

    Article  PubMed  CAS  Google Scholar 

  14. Fahn S, Elton R, Members of the UPDRS Development Committee (1987) The unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153–63, 293–304

  15. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198

    Article  PubMed  CAS  Google Scholar 

  16. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a Frontal Assessment Battery at bedside. Neurology 55:1621–1626

    Article  PubMed  CAS  Google Scholar 

  17. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure of functioning and well being for individuals with Parkinson’s disease. Qual Life Res 4:241–248

    Article  PubMed  CAS  Google Scholar 

  18. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62

    Article  PubMed  CAS  Google Scholar 

  19. McDowell I, Newell C (1996) Measuring health: a guide to rating scales and questionnaires. Oxford University Press, New York

    Google Scholar 

  20. Measso GF, Cavarzeran F, Zappalà G, Lebowitz BD, Pirozzolo FJ, Amaducci LA et al (1993) The Mini-Mental State Examination: normative study of a random sample of Italian population. Dev Neuropsychol 9:77–85

    Article  Google Scholar 

  21. Appollonio I, Leone M, Isella V, Piamarta F, Consoli T, Villa ML et al (2005) The Frontal Assessment Battery (FAB): normative values in an Italian population sample. Neurol Sci 26:108–116

    Article  PubMed  CAS  Google Scholar 

  22. Istituto Nazionale di Statistica (2008) Tavole di mortalità della popolazione residente

  23. Poewe W, Mahlknecht P (2009) The clinical progression of Parkinson’s disease. Parkinsonism Relat Disord 15:S28–S32

    Article  PubMed  Google Scholar 

  24. Schrag A, Dodel R, Spottke A, Bornschein B, Siebert U, Quinn NP (2007) Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 22:938–945

    Article  PubMed  Google Scholar 

  25. Maetzler W, Liepelt I, Liepelt I, Berg D (2009) Progression of Parkinson’s disease in the clinical phase: potential markers. Lancet Neurol 8:1158–1171

    Article  PubMed  CAS  Google Scholar 

  26. Chaudhuri KR, Prieto-Jurcynska C, Naidu Y, Mitra T, Frades-Payo B, Tluk S et al (2010) The non-declaration of nonmotor symptoms of Parkinson’s disease to health care professionals: an international study using the nonmotor symptoms questionnaire. Mov Disord 25:697–701

    Article  Google Scholar 

  27. Trenkwalder C, Kies B, Rudzinska M et al (2011) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99

    Article  PubMed  Google Scholar 

  28. Hoops S, Nazem S, Siderowf AD et al (2009) Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 73(21):1738–1745

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

A. Antonini has received honoraria for consulting services and symposia from Abbott, Boehringer Ingelheim, GSK, Lundbeck, UCB, Novartis and Merck Serono; P. Barone has received honoraria for consulting services and symposia from Boehringer Ingelheim; R. Marconi has received honoraria for consulting services and symposia from Boehringer Ingelheim; L. Morgante has received honoraria for consulting services and symposia from Boehringer Ingelheim; C. Colosimo has received honoraria for consulting services and symposia from Boehringer Ingelheim; and all other authors have nothing to disclose.

Ethical standards

The study was approved by the Ethic Committee of each individual institution.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Angelo Antonini.

Additional information

On behalf of the PRIAMO study group.

The members of the PRIAMO study group are given in Appendix 1.

Appendices

Appendix 1: The PRIAMO study group

First name

Last name

Unit

Hospital

Town

Salvatore

Zappulla

Neurologia

Ospedale Umberto I

Enna

Clelia

Pellicano

Clinica Neurologica

Ospedale Sant’Andrea, II Facoltà di Medicina e Chirurgia, “Sapienza” Università di Roma

Roma

Sara

Meoni

Clinica Neurologica I

Day Hospital Dip. Scienze Neurologiche e Psichiatriche

Firenze

Marianna

Capecci

Clinica di Neuroriabilitazione

Ospedale Umberto I

Ancona

Natalia

Caravona

Centro Parkinson Dipartimento di Neurologia e Psichiatria e Centro di Ricerca per le Malattie Sociali (CIMS)

“Sapienza” Università di Roma

Roma

Gianni

Pezzoli

Centro Parkinson

Istituti Clinici di Perfezionamento

Milano

Vittorio

Petretta

Neurologia e Stroke

A.O.R.N. San Giuseppe Moscati

Avellino

Massimo

Pederzoli

Neurologia

Ospedale Civile

Vimercate

Fulvio

Pepe

Neurologia

Fondazione Poliambulanza

Brescia

Marianna

Amboni

 

IDC-Hermitage-Capodimonte

Napoli

Daniela

Frosini

Centro Parkinson

Azienda Ospedaliero-Universitaria Pisana

Pisa

Sergio

Zanini

Clinica Neurologica

Policlinico Universitario Udine

Udine

Giampiero

Volpe

Neurofisiopatologia Dip. Neuro Orto Traumatologia

Presidio Ospedaliero S. Luca

Vallo della Lucania

Gilda

Di Brigida

Dipartimento Neuroscienze, Oftalmologia e Genetica

Università degli Studi di Genova

Genova

Marco

Di Giovanni

U.O. di Neurologia

Ospedale Regionale

Aosta

Roberto

L’Erario

Neurologia

Ospedale Civile San Bortolo

Vicenza

Giuseppe

Ciacci

Neurologia

Policlinico Le Scotte

Siena

Antonio

Cannas

U.O.Neurologia

Policlinico Universitario di Monserrato

Monserrato, Cagliari

Luisa

Giglia

Neurologia

Azienda Ospedaliera S. Elia

Caltanissetta

Alfredo

Petrone

Neurologia

Presidio Ospedaliero Annunziata

Cosenza

Stefano

Amidei

Neurologia

Ospedale Ramazzini

Carpi

Giorgio

Trianni

Neurologia

P.O. F. Ferrari

Casarano

Giovanni

Cossu

Centro Parkinson -U.O.Neurologia

Azienda Ospedaliera G.BROTZU

Cagliari

Maria

Bloise

Dip.to Scienze Neurologiche

Policlinico Umberto I Univ.La Sapienza

Roma

Chiara

Logi

U.O Neurologia

Ospedale Versilia

Camajore

Francesco

Soleti

Clinica Neurologica

Università Cattolica S. Cuore Policlinico Gemelli

Roma

Michele

Abrignani

U.O. Neurologia

Ospedale di Marsala ASP TP/2

Marsala

Rossana

Scala

Neurologia

Ospedale S. Maria Loreto Nuovo

Napoli

Franco

Pennisi

Neurologia

Ospedale di Castelvetrano

Castelvetrano

Lucia

Grasso

Neurologia

Ospedale della Misericordia

Grosseto

Francesca

Preda

Neurologia Dip. Neuroscienze applicate alla clinica

Ospedale Sant’Anna

Ferrara

Giacomo

Gurgone

U.O. Neurologia

Az. Osp. S.Giovanni di Dio

Agrigento

Mario

Zappia

Clinica Neurologica I

Policlinico Universitario

Catania

Stefania

Lanfranchi

Neurologia

Ospedale S. Antonio Abate Gallarate

Gallarate

Tania

Avarello

Centro per lo studio delle M.Extrapiramidali

O.R. Villa Sofia

Palermo

Francesca

Morgante

Dipartimento di Neuroscienze, Scienze psichiatriche ed Anestesiologiche

Università di Messina

Messina

Paolo

Stanzione

Dept. Neuroscience

Università di Roma Tor Vergata

Roma

Augusto

Scaglioni

Div. Neurologia

Ospedale di Vaio

Fidenza

Sabina

Capellari

Centro per lo studio e la cura delle malattie extrapiramidali

Dipartimento Scienze Neurologiche Università di Bologna

Bologna

Monia

Blundo

U.O. Neurologia

P.O. Guzzardi

Vittoria

Lucia

Antonutti

Clinica Neurologica

Ospedale di Cattinara

Trieste

Pasqualino

Simone

Neurologia

Ospedale Casa Sollievo della Sofferenza

San Giovanni Rotondo

Paola

Soliveri

Neurologia I

Istituto Nazionale Neurologico C. Besta

Milano

Biagio

Troianello

Neurologia

Istituto Clinico Città di Brescia

Brescia

Mattia Anna

Iellamo

U.O. Neurologia

Ospedale G. Iazzolino

Vibo Valentia

Alessandro

Mauro

Neurologia

Istituto Scientifico San Giuseppe

Piancavallo

Maurizio

Zibetti

Dipartimento Neuroscienze

Università degli Studi di Torino

Torino

Giuseppe

Nastasi

Neurologia

Az. Osp. Papardo

Messina

Appendix 2

Steering committee

Angelo Antonini:

Department for Parkinson’s disease IRCCS San Camillo, Venezia

Paolo Barone:

Scuola Medica Salernitana, Università di Salerno, Salerno; IDC-Hermitage-Capodimonte, Napoli

Carlo Colosimo:

Università La Sapienza, Roma

Roberto Marconi:

Ospedale della Misericordia, Grosseto

Letterio Morgante:

Dipartimento di Neuroscienze, Scienze Psichiatriche ed Anestesiologiche, Università di Messina, Italy.

Sponsorship

  • Tania Corbetta, Arina Dumitriu, Boehringer Ingelheim, Milan, Italy.

Project management, statistical analyses, and data management

  • Simona Sgarbi, project leader MediData Studi e Ricerche, Modena

  • Andrea Rapisarda, clinical project manager MediData Studi e Ricerche, Modena

  • Sara Rizzoli, Lucia Simoni, statisticians MediData Studi e Ricerche, Modena

  • Luca Zanoli, clinical data manager MediData Studi e Ricerche, Modena

  • Alessandra Manfredi, clinical operation specialist MediData Studi e Ricerche, Modena, Italy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Antonini, A., Barone, P., Marconi, R. et al. The progression of non-motor symptoms in Parkinson’s disease and their contribution to motor disability and quality of life. J Neurol 259, 2621–2631 (2012). https://doi.org/10.1007/s00415-012-6557-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-012-6557-8

Keywords

Navigation